NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Skin: First-line metastatic melanoma (CheckMate 067)

Free question published 15 November 2026

SkinFirst-line metastatic melanoma (CheckMate 067)

A 55-year-old man presents with newly diagnosed unresectable stage IV BRAF wild-type cutaneous melanoma. He has an excellent performance status, normal organ function and no autoimmune disease, and prioritises the best chance of long-term survival. Citing CheckMate 067, which first-line systemic therapy is most appropriate?

  1. ASingle-agent vemurafenib
  2. BCombination nivolumab plus ipilimumab
  3. CDacarbazine chemotherapy
  4. DDabrafenib plus trametinib
  5. ESingle-agent ipilimumab checkpoint inhibitor monotherapy

Why B is correct

CheckMate 067 showed that combination nivolumab plus ipilimumab gave the highest 5-year overall survival (52%) compared with nivolumab alone (44%) and ipilimumab alone (26%), establishing combination immune checkpoint inhibition as a first-line standard for advanced melanoma irrespective of BRAF status. For a fit patient seeking the best long-term survival, combination therapy is the most appropriate first-line option.

And why the others are not

  • AIncorrect: vemurafenib is a BRAF inhibitor with no role in BRAF wild-type disease.
  • CIncorrect: dacarbazine is markedly inferior to modern immunotherapy and is not a preferred first-line option.
  • DIncorrect: dabrafenib plus trametinib requires a BRAF V600 mutation, which this BRAF wild-type patient does not have.
  • EIncorrect: single-agent ipilimumab gave the lowest 5-year survival (26%) of the three arms.

Source CheckMate 067 - Combined nivolumab and ipilimumab in advanced melanoma — Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535-1546.

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing